The management of dermatomyositis: Current treatment options

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 5, 2004, Pages 1083-1099

  Sontheimer, Richard D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Aminoquinoline antimalarials; Amyopathic; Azathioprine; Biological therapy; Chloroquine; Classical dermatomyositis; Clinically amyopathic dermatomyositis; Cutaneous dermatomyositis; Cyclosporin; Dermatomyositis; Dermatomyositis skin disease; Diaminodiphenylsulfone (dapsone); Eculizumab; Etanercept; Hydroxychloroquine; Hypomyopathic dermatomyositis; Infliximab; Methotrexate; Mycophenolate; Quinacrine

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIPRURITIC AGENT; AZATHIOPRINE; BENZOCAINE; CETIRIZINE; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; DIPHENHYDRAMINE; DOXEPIN; EFALIZUMAB; EMOLLIENT AGENT; ETANERCEPT; FEXOFENADINE; HYDROXYCHLOROQUINE; HYDROXYZINE; IMMUNOGLOBULIN; INFLIXIMAB; LORATADINE; MEPACRINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PRAMOCAINE; PREDNISONE; RITUXIMAB; TACROLIMUS; UNINDEXED DRUG;

CLINICAL FEATURE; DERMATOLOGY; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; INTERSTITIAL LUNG DISEASE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; MORBIDITY; MUSCLE WEAKNESS; PATIENT CARE; PATIENT COUNSELING; PATIENT EDUCATION; PHYSICAL DISABILITY; PROGNOSIS; REVIEW; RISK ASSESSMENT; SKIN DISEASE; SUNLIGHT PROTECTION; SYMPTOM; TREATMENT OUTCOME; UNITED STATES;

DERMATOMYOSITIS; FORECASTING; HUMANS; MODELS, BIOLOGICAL; TECHNOLOGY, PHARMACEUTICAL;

EID: 2542578780     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.5.1083     Document Type: Review

References (79)

1. ISAACS D FD: Seven alternatives to evidence based medicine. Br. Med. J. (1999) 319:1618.
2. EUWER RL, SONTHEIMER RD: Dermatomyositis (Chapter 2). In: Cutaneous Manifestations of Rheumatic Diseases (1st edn). Sontheimer RD, Provost TT (Eds), Williams & Wilkins, Baltimore, USA (2003).
3. Cutaneous manifestations of rheumatic diseases (2nd edn). Sontheimer RD, Provost TT (Eds), Lippincott Williams & Wilkins, Philadelphia, USA (2003).
4. Dermatological signs of internal disease (3rd edn). Callen JP, Jorrizo JL (Eds), WB Saunders, Philadelphia, USA (2003).
5. Skin Signs of Systemic Disease (3rd edn). Braverman IM (Ed.), WB Saunders, Philadelphia, USA (1998).
6. Dermatology (1st edn). Bolognia JL, Jorrizo JL, Rapini RP (Eds), Mosby, London, UK (2003).
7. SONTHEIMER RD, COSTNER M: Dermatomyositis (Chapter 172). In: Dermatology in General Medicine (6th edn). Freedberg IM, Eisen AZ, Wolff K et al. (Eds), McGraw-Hill, New York, USA (2002).
8. COSTNER M, PROVOST TT, SONTHEIMER RD: Lupus erythematosus. In: Cutaneous Manifestations of Rheumatic Diseases (2nd edn). Lippincott Williams & Wilkins, Philadelphia, USA (2003).
9. WAGNER B, KAGAN-HALLET KS, RUSSELL IJ et al.: Concomitant presentation of adermatopathic dermatomyositis, statin myopathy, fibromyalgia syndrome, piriformis muscle myofascial pain syndrome, and diabetic neuropathy. J. Musculoskelet. Pain (2003) 11(2):25-30.
10. DALAKAS MC, HOHLFELD R: Diagnostic criteria for polymyositis and dermatomyositis. Lancet (2003) 362(9397):1763.
11. EUWER RL, SONTHEIMER RD: Amyopathic dermatomyositis (dermatomyositis sine myositis) Presentation of six new cases and review of the literature. J. Am. Acad. Dermatol. (1991) 24:959-966.
12. DAWKINS MA, JORRIZO JL, WALKER FO et al.: Dermatomyositis: a dermatology-based case series. J. Am. Acad. Dermatol. (1998) 38(3):397-404.
13. SONTHEIMER RD: Cutaneous features of classical dermaytomyositis and amyopathic dermatomyositis. Curr. Opin. Rheumatol. (1999) 11:475-482.
14. SONTHEIMER RD: Would a new name hasten the acceptance of clinically-amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J. Am. Acad. Dermatol. (2002) 46:626-636.
15. SONTHEIMER RD: Dermatomyositis. an overview of recent progress with emphasis on dermatological aspects. Dermatol. Clin. (2002) 20:387-408.
16. COHEN JB: Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. Int. J. Dermatol. (2002) 41:182-184.
17. EL-AZHARY R, PAKZAD SY: Amyopathic dermatomyositis: retrospective review of 37 cases. J. Am. Acad. Dermatol. (2002) 46:560-565.
18. SONTHEIMER RD, MIYAGAWA S: Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis. J. Am. Acad. Dermatol. (2003) 48(5):797-798.
19. HIGH WA, COHEN JB, MURPHY BA, COSTNER MI: Fatal interstitial pulmonary fibrosis in anti-Jo-1-negative amyopathic dermatomyositis. J. Am. Acad. Dermatol. (2003) 49:295-298.
20. TARGOFF IN, TRIEU EP, SONTHEIMER RD: Autoantibodies to 155 kD and Se autoantigens in patients with clinically-amyopathic dermatomyositis. Arthritis Rheum. (2000) 43(Suppl. 9):S194.
21. SATO S, SUWA A, KUWANA M et al.: Clinical and immunological associations of autoantibodies to the 140 kDa polypeptide (the US autoantigen) in patients with clinically amyopathic dermatomyositis. Arthritis Rheum. (2003)48:S102.
22. LOVE LA, LEFF RL, FRASER DD et al.: A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) (1991) 70:360-374.
23. WATANABE C, OKUBO Y, OHI T et al.: A case of dermatomyositis associated with mechanic's hand. J. Dermatol. (2000) 27(11):711-716.
24. CAPRONI M, CARDINALI C, PARODI A et al.: Amyopathic dermatomyositis - a review by the Italian group of immunodermatology. Arch. Dermatol. (2002) 138(1):23-27.
25. TRAUTMANN C, ABDEL-NASER MB, SOEHNCHEN R et al.: Pre-myopathic versus amyopathic dermatomyositis. 2 personal cases and review of the literature. Hautarzt (1995) 46(1):47-52.
26. TING WW, SONTHEIMER RD: Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations. Lupus (2001) 10:171-184.
27. SONTHEIMER RD, GEERS DL: Skin disease in dermatomyositis-What patients and their families often want to know. Derm. Online J. (2002) 20:387-408.
28. YOSHIMASU T, OHTANI T, SAKAMOTO T et al.: Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur. J. Dermatol. (2002) 12(1):50-52.
29. WALKER SL, KIRBY B, CHALMERS RJG: The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J. Dermatol. (2002) 147(2):405-406.
30. BOEHNCKE WH, OCHSENDORF F. PAESLACK I et al.: Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases. Eur. J. Dermatol. (2002) 12(6):577-580.
31. PELLE MT, CALLEN JP: Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch. Dermatol. (2002) 138(9):1231-1233.
32. MARMOR MF, CARR RE, EASTERBROOK M et al.: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology (2002) 109(7):1377-1382.
33. MARMOR MF: New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum. (2003) 48(6):1764.
34. KONOHANA A, KAWASHIMA J: Successful treatment of dermatomyositis with dapsone. Clin. Exp. Dermatol. (1994) 19(4):367.
35. SADAYAMA T, MIYAGAWA S, SHIRAI T: Low-dose intravenous immumoglobulin therapy for intractable dermatomyositis skin lesions. J. Dermatol (1999) 26(7):457-459.
36. NUNEZ M, BOIXEDA P. MIRALLES ES et al.: Pulsed dye laser treatment in lupus erythematosus telangiectoides [letter]. Br. J. Dermatol. (1995) 133(6):1010-1011.
37. RAULIN C, SCHMIDT C, HELLWIG S: Cutaneous lupus erythematosus-treatment with pulsed dye laser. Br. J. Dermatol. (1999) 141(6):1046-1050.
38. NASSIM JR, CONNOLLY CK: Treatment of calcinosis universalis with aluminium hydroxide. Arch. Dis. Child. (1970) 45:118-121.
39. WANG WJ, LO WL, WONG CK: Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminum hydroxide therapy. Arch. Dermatol. (1988) 124:1721-1722.
40. NAKAGAWA T, TAKAIWA T: Calcinosis cutis in juvenile dermatomyositis responsive to aluminum hydroxide treatment. J. Dermatol. (1993) 20:558-560.
41. DENT CE, STAMP TCB: Treatment of calcinosis circumscripta with probenecid. Br. Med. J. (1972) i:216.
42. SKUTERUD E, SYDNES OA, HAAVIK TK: Calcinosis in dermatomyositis treated with probenecid. Scand. J. Rheumatol. (1981) 10:92-94.
43. ROWELL NR, GOODFIELD MJD: The 'Connective Tissue Diseases'. In: Textbook of Dermatology Champion RH, Burton JL, Ebling FJG (Eds), Blackwell Scientific Publications, London, UK (1992):2163-2294.
44. BERGER RG, FEATHERSTON GL, RAASON RH: Treatment of calcinosis universalis with low dose warfarin. Am. J. Med. (1987) 83:72-76.
45. MARTINEZ-CORDER0 E, LOPEZ-ZEPEDA J, CHOZA-ROMERO F: Calcinosis in childhood dermatomyositis [letter]. Clin. Exp. Rheumatol. (1990) 8:198-200.
46. OLIVERI MB, PALERMO R, MAUTALEN C et al.: Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J. Rheumatol. (1996) 23(12):2152-2155.
47. LASSOUED K, SAIAG P. ANGLADE MC et al.: Failure of warfarin in treatment of calcinosis universalis. Am. J. Med. (1988) 84:795-796.
48. HERD JK, VAUGHAN JH: Calcinosis universalis complicating dermatomyositis. Arthritis Rheum. (1964) 7:259-271.
49. TABORN J, BOLE GG, THOMPSON GR: Colchicine suppression of local and systemic inflammation due to calcinosis universalis in chronic dermatomyositis. Ann. Intern. Med. (1978) 89:648-649.
50. MUKAMEL M, HOREV G, MIMOUNI M: New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J. Pediatr (2001). 138(5):763-766.
51. SHEARIN JC, PICKRELL K: Surgical treatment of subcutaneous calcifications of polymyositis or dermatomyositis. Ann. Plast. Surg. (1980) 5:381-385.
52. RAHMAN P, GLADMAN DD, UROWITZ MB: Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J. Rheumatol. (1998) 25:1716-1719.
53. JEWELL ML, MCCAULIFFE DP: Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J. Am. Acad. Dermatol. (2000) 42(6):983-987.
54. ISHII N, ONO H, KAWAGUCHI T et al.: Dermatomyositis and pregnancy. Case report and review of the literature. [Review]. Dermatologica. (1991) 183:146-149.
55. OHNO T, IMAI A, TAMAYA T: Successful outcomes of pregnancy complicated with dermatomyositis case reports. Gynecol. Obstet. Invest. (1992) 33:187-189.
56. KRAIN L: Dermatomyositis in six patients without initial muscle involvement. Arch. Dermatol. (1975) 111:241-245.
57. EUWER R, SONTHEIMER RD: Amyopathic dermatomyositis-a review. J. Invest. Dermatol. (1993) 100:124S-127S.
58. SONTHEIMER RD: A portable digital microphotography unit for rapid bedside documentation of periungual nailfold capillary changes seen in autoimmune connective tissue diseases. J. Rheumatol. (2004) 31(3):539-544.
59. CROWSON AN, MAGRO CM: The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis. Hum. Pathol. (1996) 27(1):15-19.
60. MASCARO JM Jr, HAUSMANN G, HERRERO C et al.: Membrane attack complex deposits in cutaneous lesions of dermatomyositis. Arch. Dermatol. (1995) 131(12):1386-1392.
61. THUNE P: The coexistence of amyopathic dermatomyositis and fibromyalgia. Acta. Derm. Venereol. (2000) 80(6):453-454.
62. LANGLO L: The efficacy of local application of chloroquine and mepacrine in preventing the effects of ultraviolet rays on human skin. Acta. Dermatol. Venerol. (1957) 27:85.
63. KUTINTSCHEV M, CHLEBAROV S: Treatment of lupus erythematosus by iontophoresis with plaquenil. Z. Haut. Geschlechtskr. (1967) 42(22):676-678.
64. EVERETT MA, COFFEY CM: Intradermal administration of chloroquine. Arch. Dermatol. (1961) 83:977-979.
65. WERTH VP, CALLEN JP, ANG G et al.: Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: Implications for a unique pathogenesis. J. Invest. Dermatol. (2002) 119(3):617-620.
66. HENGSTMAN GJ, VAN DEN HOOGEN FH, BARRERA P et al.: Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur. Neurol. (2003) 50(1):10-15.
67. SAADEH CK: One member's story: Enbrel use restored his strength. The Outlook for the Inflmmatory Myopathies (Myositis Association of America) June 11 (2000). Myositis Association of America.
68. HENGSTMAN G, VAN DEN HOOGEN F, VAN ENGELEN B et al.: Anti-TNF blockade with infliximab (Remicade) in polymyositis and dermatomyositis. The Outlook for the Inflammatory Myopathies March 17 (2001). Myositis Association of America.
69. NZEUSSEU A., DUREZ P, HOUSSIAU F et al: Successful use of infliximab in a case of refractory juvenile dermatomyositis. Arthritis Rheum. (2001) 44(9):S90-S-90.
70. BLEUMINK GS, TER BORG EJ, RAMSELAAR CG et al.: Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (2001) 40(11):1317-1319.
71. ALI Y, SHAH S: Infliximab-induced systemic lupus erythematosus. Ann. Int. Med. (2002) 137(7):625-626.
72. KAPLAN M: Eculizumab (Alexion). Curr. Opin. Investig. Drugs (2002) 3(7):1017-1023.
73. SHAW T, QUAN J, TOTORITIS MC et al.: B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum. Dis. (2003) 62(Suppl. 2):55-59.
74. PERROTTA S, LOCATELLI F, LA MANNA A et al.: Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br. J. Haematol. (2002) 116(2):465-467.
75. KNEITZ C, WILHELM M, TONY HP: Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology (2002) 206(5):519-527.
76. GOEBELER M, HERZOG S, BROCKER EB et al.: Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br. J. Dermatol. (2003) 149(4):899-901.
77. SALOPEK TG, LOGSETTY S, TREDGET EE: Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J. Am. Acad. Dermatol. (2002) 47(5):785-788.
78. GERDESMEYER L, WAGENPFEIL S, HAAKE M et al.: Extracorporeal shock wave therapy for the treatment of chronic calcifying tendonitis of the rotator cuff: a randomized controlled trial. JAMA (2003) 290(19):2573-2580.
79. COSENTINO R, DE STEFANO R, SELVI E et al.: Extracorporeal shock wave therapy for chronic calcific tendinitis of the shoulder: single blind study. Ann., Rheum. Dis. (2003) 62(3):248-250.